filmov
tv
2023 WMIF | Disruptive Dozen #11
Показать описание
Toward a simple, cost-effective blood test for Alzheimer’s disease
Researchers are working develop a simple, cost-effective way to diagnose Alzheimer’s disease and other neurodegenerative conditions decades before the onset of physical symptoms — when the course of the disease could potentially be halted or perhaps even reversed. Such a diagnostic test could rapidly accelerate the development of effective treatments for these diseases, and also form a key piece of the puzzle for lowering the future public health burden of Alzheimer’s disease, which is projected to skyrocket by 2050.
Researchers are working develop a simple, cost-effective way to diagnose Alzheimer’s disease and other neurodegenerative conditions decades before the onset of physical symptoms — when the course of the disease could potentially be halted or perhaps even reversed. Such a diagnostic test could rapidly accelerate the development of effective treatments for these diseases, and also form a key piece of the puzzle for lowering the future public health burden of Alzheimer’s disease, which is projected to skyrocket by 2050.
2023 WMIF | Disruptive Dozen #12
2023 WMIF | Disruptive Dozen
2023 WMIF | Disruptive Dozen #1
2023 WMIF | Disruptive Dozen #11
2023 WMIF | Disruptive Dozen #8
2023 WMIF | Disruptive Dozen #4
2023 WMIF | Disruptive Dozen #10
2023 WMIF | Disruptive Dozen #6
2023 WMIF | Disruptive Dozen #7
2023 WMIF | Disruptive Dozen #3
2023 WMIF | Disruptive Dozen #9
2023 WMIF | Disruptive Dozen #5
2023 WMIF | Disruptive Dozen #2
2022 WMIF | Disruptive Dozen #5
2023 WMIF | A Deep Dive on Cell Therapy: Applying Lessons Learned from First Gen. Cell Therapies
2016 WMIF | Disruptive Dozen – 1
2023 WMIF | The Disruptors: The Biologic Revolution in Cancer Continues
2023 WMIF | Biopharmaceuticals & The Inflation Reduction Act: A Status Report on IRA Implementat...
2023 WMIF | The Dr. Is In | Inflammation and Immunology: Balancing the Risks and Rewards
2023 WMIF | The Inflation Reduction Act: The Emerging Implications for Biopharmaceutical Innovation
2023 FIRST LOOK | Jordan Smoller, MD, ScD
2023 WMIF | Opening Remarks - Jonathan Kraft, Anne Klibanski, Brian Moynihan
2023 WMIF | A Deep Dive on Genetic Modalities for CNS Diseases: The Genetic Medicine Frontier
Paul Anderson, MD, PhD, Interim Chief Academic Officer, speaks at #WMIF2023
Комментарии